Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review.
| Autor: | Aguirre AS; School of Medicine, Universidad San Francisco de Quito, Quito, ECU., Astudillo Moncayo OM; General Medicine, University of Cuenca, Cuenca, ECU., Mosquera J; Medicine, Universidad de las Américas, Quito, ECU., Muyolema Arce VE; Medicine, Universidad de Guayaquil, Guayaquil, ECU., Gallegos C; Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, ECU., Ortiz JF; Neurology, Spectrum Health Medical Group/Michigan State University, Quito, ECU., Andrade AF; Medicine, Universidad San Francisco de Quito, Quito, ECU., Oña S; School of Medicine, Universidad San Francisco de Quito, Quito, ECU., Buj MJ; Psychiatry, Medical Chamber, Belgrade, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Jun 03; Vol. 15 (6), pp. e39903. Date of Electronic Publication: 2023 Jun 03 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.39903 |
| Abstrakt: | Facioscapulohumeral muscular dystrophy (FSHD) is the third most common type of muscular dystrophy. This disease presents as a slowly progressive asymmetric muscle weakness that involves the facial, scapular, and upper arm muscles mainly. Currently, there is no established consensus on this disease treatment in terms of medications. We assessed the response to the treatment of the drugs utilized in clinical trials by performing a systematic literature review in English using the preferred reporting items for systematic reviews (PRISMA) and meta-analyses. We only used human clinical trials in patients diagnosed with FSHD that received consistent pharmacological treatment. We included 11 clinical trials that fulfilled our criteria. We concluded that albuterol had statistically significant results in three out of four clinical trials, with improved elbow flexors muscle strength. Vitamin C, vitamin E, zinc gluconate, and selenomethionine showed significant improvement in the maximal voluntary contraction and endurance limit time of quadriceps muscle. At the same time, diltiazem and MYO-029 demonstrate no improvement in function, strength, or muscle mass. Losmapimod, currently in phase I of the ReDUX4 trial, showed promising results. Peradventure, more clinical trials are still needed to address this subject. Nevertheless, this review provides a clear and concise update on the treatment for this disease. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Aguirre et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|